People with severe hemophilia A are at risk for prolonged bleeding events that can cause serious complications. To prevent these bleeding events, most people with this condition get injections of a ...
Efanesoctocog alfa provides high sustained factor VIII activity by overcoming the von Willebrand factor–imposed half-life ceiling. The efficacy, safety, and pharmacokinetics of efanesoctocog alfa for ...
The National Institute for Health and Care Excellence (NICE) has published a final draft guidance recommending efanesoctocog alfa for treating and preventing bleeding episodes in people aged 2 years ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback